medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2025, Número 2

Siguiente >>

Cardiovasc Metab Sci 2025; 36 (2)


Conexión Metabólica-Adiposa-Cardio-Arterial-Renal-Enterohepática-Neurológica en hipertensión arterial (MACARENHA): posicionamiento para el nuevo enfoque de prevención, diagnóstico, tratamiento y seguimiento de los pacientes que viven con hipertensión arterial en México

Alcocer-Díaz-Barreiro L, Alcocer A, Álvarez-López H, Ancona-Vadillo AE, Antonio-Villa NE, Barquera S, Borrayo-Sánchez G, Cardona-Müller D, Cardona-Muñoz E, Cantoral-Farfán E, Cigarroa-López JÁ, Cruz-Montalvo A, Chávez-Mendoza A, Chávez-Negrete A, Saturno-Chiu G, Delgado-Félix SE, Díaz-Díaz E, Díaz-Aguilera MÁ, Díaz-Domínguez E, Duarte-Vega M, Enciso-Muñoz JM, Escudero-Cañedo X, Ferrari GE, Flores-Morales A, Galván-Oseguera H, García-Fernández R, García-Méndez R, García-López SM, Gómez-Álvarez E, González-Coronado VJ, Gracia-Ramírez Á, Heredia-Lavín JM, López-Meneses M, Lupercio-Mora K, Madrid-Miller A, Magaña-Serrano JA, Martínez-Juárez DH, Meaney-Mendiolea E, Ortiz-Fernández P, Palomo-Piñón S, Parcero-Valdez JJ, Pazos-Pérez F, Pavía-López AA, Puente-Barragán A, Rechy-Rivera A, Rey-García L, Ricalde-Alcocer A, Rosas-Peralta M, Santiago-Velázquez MÁ, Silva M, Toledo-Ortiz R, Villaseñor-Hidalgo R

Idioma: Inglés [English version]
Referencias bibliográficas: 37
Paginas: 79-93
Archivo PDF: 415.13 Kb.





REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020; 16 (4): 223-237. doi: 10.1038/s41581-019-0244-2.

  2. Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, Muiesan ML et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024; 126: 1-15. doi: 10.1016/j.ejim.2024.05.033.

  3. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019; 139 (16): e840-e878. doi: 10.1161/CIR.0000000000000664.

  4. Meaney E, Pérez-Robles E, Ortiz-Flores M, Perez-Ishiwara G, Meaney A, Munguía L et al. Overweight, obesity, and age are the main determinants of cardiovascular risk aggregation in the current mexican population: the FRIMEX III study. J Clin Med. 2024; 13 (8): 2248. doi: 10.3390/jcm13082248.

  5. Palomo-Piñón S, Antonio-Villa NE, García-Cortés LR, Moreno-Noguez M, Alcocer L, Álvarez-López H et al. Patients living with arterial hypertension in mexico: first insights of the mexican registry of arterial hypertension (RIHTA Study). Am J Hypertens. 2024; 37 (7): 503-513. doi: 10.1093/ajh/hpae024.

  6. McCarthy CP, Bruno RM, Rahimi K, Touyz RM, McEvoy JW. What is new and different in the 2024 European Society of Cardiology guidelines for the management of elevated blood pressure and hypertension? Hypertension. 2025; 82 (3): 432-444. doi: 10.1161/HYPERTENSIONAHA.124.24173.

  7. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45 (38): 3912-4018. doi: 10.1093/eurheartj/ehae178. Erratum in: Eur Heart J. 2025 Apr 7;46(14):1300. doi: 10.1093/eurheartj/ehaf031.

  8. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111-188. doi: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020; 41 (44): 4255.

  9. Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013; 7 (1): 14-24. doi: 10.1007/s11684-013-0262-6.

  10. Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Sig Transduct Target Ther. 2023; 8: 152. Available in: https://doi.org/10.1038/s41392-023-01400-z

  11. American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care. 2025; 48 (Suppl. 1): S27-S49. Available in: https://doi.org/10.2337/dc25-S002

  12. Lee H, Rhee TM, Choi JM, Choi SY, Kim DW. The close link between obesity and cardiovascular disease: current insights and remaining challenges. Endocrinol Metab Clin North Am. 2025; 54 (1): 175-192.

  13. Xinying Hu, Peng Han, Yong Liu. Metabolic status and hypertension: the impact of insulin resistance-related indices on blood pressure regulation and hypertension risk. Journal of the American Nutrition Association. 2025: 1-11.

  14. Basurto ML, Abdo-Francis M, Aguilar-Salinas CA, Balcázar-Hernández LJ, Borrayo-Sánchez G, Castro-Narro GE et al. Dyslipidemia: recommendations for diagnosis and treatment at the first level of medical contact. Gac Med Mex. 2024; 160 (4): 354-362. English. doi: 10.24875/GMM.M24000916.

  15. Kaylan KB, Paul S. NAFLD no more: a review of current guidelines in the diagnosis and evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD). Curr Diab Rep. 2025; 25: 5. Available in: https://doi.org/10.1007/s11892-024-01558-y

  16. Dardi P, Perella CC, de Oliveira S, Aparecida ST, Rodrigues RFG, Purgatto E, et al. Changes in the intestinal microbiota induced by the postnatal environment and their association with hypertension. Pharmacological Research. 2025; 212: 107621.

  17. Psaltis JP, Marathe JA, Nguyen MT, Le R, Bursill CA, Marathe CS, et al. Incretin-based therapies for the management of cardiometabolic disease in the clinic: past, present, and future. Med Res Rev. 2025; 45 (1): 29-65.

  18. O'Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. Nat Rev Nephrol. 2023; 19 (3): 153-167. doi: 10.1038/s41581-022-00654-0.

  19. Laule C, Rahmouni K. Leptin and associated neural pathways underlying obesity-induced hypertension. Compr Physiol. 2025; 15 (1): e8. doi: 10.1002/cph4.8.

  20. Schunkert H, Di Angelantonio E, Inouye M, Patel RS, Ripatti S, Widen E et al. Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease: A clinical consensus statement of the ESC Council on Cardiovascular Genomics, the ESC Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology. Eur Heart J. 2025; 46 (15): 1372-1383. doi: 10.1093/eurheartj/ehae649.

  21. Theodorakopoulou M, Ortiz A, Fernandez-Fernandez B, Kanbay M, Minutolo R, Sarafidis PA. Guidelines for the management of hypertension in CKD patients: where do we stand in 2024? Clin Kidney J. 2024; 17 (Suppl 2): 36-50. doi: 10.1093/ckj/sfae278.

  22. Burlacu A, Kuwabara M, Brinza C, Kanbay M. Key updates to the 2024 ESC hypertension guidelines and future perspectives. Medicina. 2025; 61 (2): 193.

  23. Cohen JB. What is new in the ESC hypertension guideline? Hypertension. 2025; 82 (1): 11-13. doi: 10.1161/HYPERTENSIONAHA.124.23724.

  24. Lim H, Agustian H, Febriana V, Inda SA. Sacubitril/valsartan role in patients with resistant hypertension: a systematic review. Hellenic Journal of Cardiology, 2025.

  25. Kallash M, Frishman W. Investigating the relationship between sodium-glucose cotransporter-2 (SGLT2) inhibitors and blood pressure. Cardiol Rev. 2025. doi: 10.1097/CRD.0000000000000861.

  26. Iyengar SS, Rahul V. Lipidology in hypertension. Hypertension: Known & Less Known Facts. 2025, 107.

  27. Fisher NDL, Kirtane AJ. Renal denervation for hypertension. Nat Rev Cardiol. 2025.

  28. RR Dian Tristiana, Ika Nur Pratiwi, Praba Diyan Rachmawati, Lailatun Nimah, Iqlima Kurnia, Aria Aulia Nastiti et al. Digital health intervention to improve healthy lifestyle and to prevent complications in hypertension patients: a systematic review. Journal of Liaquat University of Medical & Health Sciences Special Issue. 2025: 22-27.

  29. Hamaya R, Wang M, Hertzmark E, Cook NR, Manson JE, Sun Q et al. Modifiable lifestyle factors in the primordial prevention of hypertension in three US cohorts. European Journal of Internal Medicine, 2025; 132: 55-66.

  30. Bredehorst M, González-González AI, Schürmann L, Firmansyah D, Muth C, Haasenritter J et al. Recommendations for the primary prevention of atherosclerotic cardiovascular disease in primary care: a systematic guideline review. Front Med (Lausanne). 2025; 11: 1494234.

  31. Schwalm JD, Joseph P, Leong D, Lopez-Lopez JP, Onuma O, Bhatt P et al. Cardiovascular disease in the Americas: optimizing primary and secondary prevention of cardiovascular disease series: cardiovascular disease in the Americas. Lancet Reg Health Am. 2025; 42: 100964.

  32. Rojas-Martínez R, Escamilla-Nuñez C, Castro-Porras L, Gómez-Velasco D, Romero-Martínez M, Aguilar-Salinas CA. Cardiovascular risk factors and vascular complications in adults with earlyand late-onset diabetes in Mexico. Ensanut 2018. Salud Publica Mex. 2024; 66 (3): 277-287. doi: 10.21149/15786.

  33. Rosas-Peralta M, Galván-Oseguera H, Alcocer L, Álvarez-López H, Cardona-Muñoz E, Palomo-Piñón S et al. Call to action! hypertension and dyslipidemia in Mexico: underestimated deadly duo. Ann Clin Hypertens. 2024; 8 (1): 007-010. doi: 10.29328/journal.ach.1001036.

  34. Kytomaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J et al. Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study. JAMA Cardiol. 2019; 4 (4): 363-369. doi: 10.1001/jamacardio.2019.0549.

  35. Akhtar Z, Trent M, Moa A, Tan TC, Frobert O, MacIntyre CR. The impact of COVID-19 and COVID vaccination on cardiovascular outcomes. Eur Heart J Suppl. 2023; 25 (Suppl A): A42-A49. doi: 10.1093/eurheartjsupp/suac123.

  36. Bautista-Arredondo S, Cerecero-García D, Macías-González F, Barrientos-Gutiérrez T. The impact of the Covid-19 vaccination policy in Mexico. A quasi-experimental effectiveness evaluation of a multi-vaccine strategy. Salud Publica Mex. 2023; 66: 78-84. doi: 10.21149/14877.

  37. INEGI. https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2024/EDR/EDR2024_1erT.pdf




2020     |     www.medigraphic.com